Novo-Nordisk A/S NVO

Novo Nordisk A/S es una empresa global de atención médica dedicada al cuidado de la diabetes. La empresa también se dedica al descubrimiento, desarrollo, fabricación y comercialización de productos farmacéuticos. Opera a través de dos segmentos comerciales: cuidado de la diabetes y la obesidad, y biofarmacéuticos. El segmento de cuidado de la diabetes y la obesidad de la empresa abarca insulina, GLP-1, otros productos relacionados con proteínas, como el glucagón, sistemas de administración de proteínas y agujas, y medicamentos antidiabéticos orales. El segmento de biofarmacéuticos de la empresa abarca las áreas terapéuticas del cuidado de la hemofilia, la terapia con hormona del crecimiento y la terapia de reemplazo hormonal. La empresa también ofrece el producto Saxenda para tratar la obesidad. Ofrece una variedad de productos, incluidos NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin y Vagifem. Hasta el 31 de diciembre de 2016, comercializaba sus productos en más de 180 países. Su estructura regional consta de dos unidades comerciales: América del Norte y Operaciones Internacionales.

Con 27 acciones de NVO (USD 1.002,92) habrías recibido USD 48,60 en dividendos en los últimos 12 meses.

NVO hizo una división de acciones (split) de 2:1 el 20 de septiembre de 2023: cada acción se convirtió en 2. Cambió la cantidad de acciones y su precio, pero no el valor total de la inversión.

• The Motley Fool 5 oct

  Here Are My Top 4 Stocks to Buy in October

  The article recommends four stocks for October investment: Viking Therapeutics for its unique monthly-dose GLP-1 weight loss drug candidate in a market expected to reach $200 billion by 2030; Alphabet for its dominant position in cloud computing AI services with 82% YoY growth and gaining market share; SoFi Technologies for strong revenue growth (40% YoY) and customer expansion despite recent setbacks; and MercadoLibre for its Amazon-like growth trajectory in Latin America with 50% YoY revenue growth despite margin pressures from free shipping initiatives.

  

• The Motley Fool 4 oct

  Better High-Yield Dividend Stock: Pfizer or Novo Nordisk?

  Both Pfizer and Novo Nordisk face significant dividend safety concerns despite high yields. Novo Nordisk (4.7% yield) leads in GLP-1 drugs but has lost market share to Eli Lilly and lacks portfolio diversity, while Pfizer (6% yield) faces patent expirations and R&D challenges. However, Pfizer's broader product portfolio and acquisition strategy make it the relatively safer choice for dividend investors, despite both stocks carrying material risk.

  

• The Motley Fool 2 oct

  Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP

  VanEck Pharmaceutical ETF (PPH) offers lower costs (0.36% expense ratio) and higher dividend yield (2%), making it better for long-term buy-and-hold investors. Invesco Pharmaceuticals ETF (PJP) delivered stronger 1-year returns (41% vs 31%) with more balanced U.S.-focused holdings, but charges higher fees (0.58%) and offers lower yield (0.9%).

  

• GlobeNewswire Inc. 2 oct

  Novo provides update on the denecimig Biologics License Application (BLA) in the US

  The FDA has extended its review of Novo Nordisk's denecimig BLA for haemophilia A treatment due to ongoing manufacturing facility remediation activities. No deficiencies were identified in clinical efficacy or safety data. Novo aims to launch denecimig in the US in H1 2027, pending regulatory approval. The delay does not impact Novo's 2026 financial outlook.

  

• The Motley Fool 2 oct

  Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

  Novo Nordisk and Pfizer are compared as pharmaceutical giants navigating different challenges. Novo Nordisk boasts superior profitability with a 33% net margin and strong cash flow, but faces pricing pressures and competition in the GLP-1 weight-loss drug market. Pfizer trades at lower valuations and is improving net income through strategic acquisitions in oncology and obesity, though it faces significant patent cliffs through 2030. The article recommends Pfizer as the better buy in 2026 based on its value metrics and improving earnings trajectory.